Transcode Therapeutics (RNAZ) Other Non-Current Assets (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Other Non-Current Assets for 7 consecutive years, with $25000.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 77.65% year-over-year to $25000.0; the trailing twelve-month figure through Mar 2026 stood at $25000.0 (down 77.65% YoY), and the FY2024 full-year result was $111856.0, changed 0.0% from the prior year.
• Other Non-Current Assets declined to $25000.0 in Q1 2026 per RNAZ's latest filing, from $455726.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $455726.0 in Q3 2025 and bottomed at $25000.0 in Q1 2026.
• Historically, Other Non-Current Assets has averaged $145599.0 across 5 years, with a median of $111856.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets surged 307.42% in 2025, then plunged 77.65% in 2026.
• Over 5 years, Other Non-Current Assets stood at $235817.0 in 2022, then plunged by 52.57% to $111856.0 in 2023, then changed by 0.0% to $111856.0 in 2024, then surged by 307.42% to $455726.0 in 2025, then tumbled by 94.51% to $25000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $25000.0, $455726.0, and $111856.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.